Minerva Neurosciences Inc
Cerrado
4.76 3.25
Resumen
Variación precio
24h
Mínimo
4.59
Máximo
4.85
Ingresos | 158M -125M |
|---|---|
P/B Media del Sector | 2.462 49.888 |
BPA | -0.36 |
Empleados | 7 |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 Meses | +124.36% upside |
Próximas Ganancias | 12 ago 2026 |
|---|
Capitalización Mercado | 3.7M 188M |
|---|---|
Apertura anterior | 1.51 |
Cierre anterior | 4.76 |
Minerva Neurosciences Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Minerva Neurosciences Inc previsión
Precio Objetivo
By TipRanks
124.36% repunte
Estimación a 12 Meses
Media 10.5 USD 124.36%
Máximo 14 USD
Mínimo 7 USD
De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Minerva Neurosciences Inc Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Beneficio antes de impuestos
Ventas
Gasto por intereses de deuda
Beneficio operativo
$
Acerca de Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
